تغییرات سایتوکاین‌های اینترلوکین ـ2 و اینترلوکین ـ12 در سلول‌های طحال موش‌های بالب‌سی به‌دنبال استفاده از یک وهله ورزش استقامتی به‌عنوان اجوانت واکسن ویروس هرپس سیمپلکس یک

1. Rathmell J C, Vander Heiden M G, Harris M H, Frauwirth K A, Thompson C B. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell. 2000; 6(3): 683-92.
2. Frauwirth K A, Thompson C B. Regulation of T lymphocyte metabolism. J Immunol. 2004; 172(8): 4661-5.
3. Miyazaki T, Liu Z J, Kawahara A, Minami Y, Yamada K, Tsujimoto Y, et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell. 1995; 81(2): 223-31.
4. Koshland M E. The coming of age of the immunoglobulin J chain. Annu Rev Immunol. 1985; 3: 425-53.
5. Giri J G, Kumaki S, Ahdieh M, Friend D J, Loomis A, Shanebeck K, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995; 14(15): 3654-63.
6. Gaffen S L, Liu K D. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004; 28(3): 109-23.
7. Marshall J D, Secrist H, DeKruyff R H, Wolf S F, Umetsu D T. IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+T lymphocytes. J Immunol. 1995; 155(1): 111-7.
8. Chehimi J, Trinchieri G. Interleukin-12: A bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol. 1994; 14(3): 149-61.
9. Khatri V P, Fehniger T A, Baiocchi R A, Yu F, Shah M H, Schiller D S, et al. Ultra-low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest. 1998; 101(6): 1373-8.
10. Koelle D M. Vaccines for herpes simplex virus infections. Curr Opin Investig Drugs. 2006; 7(2): 136-41.
11. Whitley R J, Roizman B. Herpes simplex viruses: Is a vaccine tenable? Journal of Clinical Investigation. 2002; 110(2): 145-51.
12. Liu T, Khanna K M, Chen X, Fink D J, Hendricks R L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med. 2000; 191(9): 1459-66.
13. Halford W P, Maender J L, Gebhardt B M. Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J. 2005; 2: 56.
14. Gallichan W S, Woolstencroft R N, Guarasci T, McCluskie M J, Davis H L, Rosenthal K L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. The Journal of Immunology. 2001; 166(5): 3451-7.
15. Janeway Ca Jr, Travers P, Walport M. Immunobiology: The immune system in health and disease. 5th ed. New York: Garland Science; 2001.
16. Edwards K M, Burns V E, Carroll D, Drayson M, Ring C. The acute stress-induced immunoenhancement hypothesis. Exerc Sport Sci Rev. 2007; 35(3): 150-5.
17. Rock K L, Hearn A, Chen C J, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol. 2005; 26(3): 231-46.
18. Pascoe A R, Fiatarone Singh M A, Edwards K M. The effects of exercise on vaccination responses: A review of chronic and acute exercise interventions in humans. Brain Behav Immun. 2014; 39: 33-41.
19. Rogers C J, Zaharoff D A, Hance K W, Perkins S N, Hursting S D, Schlom J, et al. Exercise enhances vaccine-induced antigen-specific T cell responses. Vaccine. 2008; 26(42): 5407-15.
20. Molanouri Shamsi M, Hassan Z M, Quinn L S, Gharakhanlou R, Baghersad L, Mahdavi M. Time course of IL-15 expression after acute resistance exercise in trained rats: Effect of diabetes and skeletal muscle phenotype. Endocrine. 2015; 49(2): 396-403. (In Persian).
21. Azimian E, Ranjbar R, Shakerian S, Habibi A, Ghafourian M. Comparison of an acute bout of combined exercise training in different intensities on tumor necrosis factor- α (TNFα) and interlokin-6 (IL-6) in active men. Sport Physiology Journal. 2016; 28: 87-102. (In Persian).
22. Nieman D C. Exercise effects on systemic immunity. Immunology and Cell Biology. 2000; 78: 496–501.
23. Magalhães J, Fraga M, Lumini-Oliveira J, Gonçalves I, Costa M, Ferreira R, et al. Eccentric exercise transiently affects mice skeletal muscle mitochondrial function. Appl Physiol Nutr Metab. 2013; 38(4): 401-9.
24. Lowder T, Padgett D A, Woods J A. Moderate exercise protects mice from death due to influenza virus. Brain Behav Immun. 2005; 19(5): 377-80.
25. Davis J M, Kohut M L, Colbert L H, Jackson D A, Ghaffar A, Mayer E P. Exercise, alveolar macrophage function, and susceptibility to respiratory infection. J Appl Physiol. 1997; 83(5): 1461-6.
26. Edwards K M, Burns V E, Adkins A E, Carroll D, Drayson M, Ring C. Meningococcal a vaccination response is enhanced by acute stress in men. Psychosomatic Medicine. 2008; 70(2): 147-51.
27. Edwards K M, Burns V E, Allen L M, McPhee J S, Bosch J A, Carroll D, et al. Eccentric exercise as an adjuvant to influenza vaccination in humans. Brain Behav Immun. 2007; 21(2): 209-17.
28. Bruunsgaard H, Hartkopp A, Mohr T, Konradsen H, Heron I, Mordhorst Ch, et al. In vivo cell-mediated immunity and vaccination response following prolonged, intense exercise. Med Sci Sports Exerc. 1997; 29(9): 1176-81.
29. Kakanis M W, Peake J, Brenu E W, Simmonds M, Gray B, Hooper S L, et al. The open window of susceptibility to infection after acute exercise in healthy young male elite athletes. Exerc Immunol Rev. 2010; 16: 119-37.
30. Long J E, Ring C, Drayson M, Bosch J, Campbell J P, Bhabra J, et al. Vaccination response following aerobic exercise: Can a brisk walk enhance antibody response to pneumococcal and influenza vaccinations? Brain Behav Immun. 2012; 26(4): 680-7.
31. Pedersen B K, Steensberg A, Schjerling P. Muscle-derived interleukin-6: Possible biological effects. J Physiol. 2001; 536(Pt 2): 329-37.
32. Black S, De Gregorio E, Rappuoli R. Developing vaccines for an aging population. Sci Transl Med. 2015, 7(281): 281-8.
33. Boraschi D, Italiani P. Immunosenescence and vaccine failure in the elderly: Strategies for improving response. Immunol Lett. 2014; 162(1 Pt B): 346-53.
34. Kuo T, Wang C, Badakhshan T, Chilukuri S, Ben Mohamed L. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine. 2014; 32(50): 6733-45.
35. St Leger A J, Hendricks R L. CD8+ T cells patrol HSV-1-infected trigeminal ganglia and prevent viral reactivation. J Neurovirol. 2011; 17(6): 528-34.
36. Rabinowich H, Herberman R B, Whiteside T L. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol. 1993; 152(2): 481-98.
37. Kaufman H L, Flanagan K, Lee C S, Perretta D J, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine. 2002; 20(13-14): 1862-9.
38. Spruance S L, Evans T G, McKeough M B, Thai L, Araneo B A, Daynes R A, et al. Th1/ Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 1995; 28(1): 39-55.
39. Xu M, Lepisto A J, Hendricks R L. CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas. J Immunol. 2004; 173(2): 1232-9.
40. Tomljenovic L, Shaw C A. Aluminum vaccine adjuvants: Are they safe? Curr Med Chem. 2011; 18(17): 2630-7.
41. Gupta R K, Siber G R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine. 1995; 13(14): 1263-76.